Havana, Cuba

Ania Cabrales Rico

This inventor holds 3 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignee: Centro De Ingenieria Genetica Y Biotecnologia. Active years: 2010-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ania Cabrales Rico. Retrieved from https://idiyas.com/inventor/ania-cabrales-rico

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 

% Patents Active = 66.7

 

 

Average Co-Inventor Count = 6.2

ph-index = 1

Forward Citations = 4(Granted Patents)


Location History:

  • Ciudad de La Habana, CU (2010)
  • Havana, CU (2013)

Company Filing History:


Years Active: 2010-2025

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Ania Cabrales Rico: Innovator in Biotechnology

Introduction

Ania Cabrales Rico is a notable inventor based in Havana, Cuba. She has made significant contributions to the field of biotechnology, particularly in the development of therapeutic peptides and methods for combating viral infections. With a total of 3 patents to her name, her work is paving the way for advancements in medical treatments.

Latest Patents

One of her latest patents is focused on an Interleukin-15 activity antagonist peptide. This invention discloses an antagonist peptide characterized by an amino acid sequence identified as SEQ ID No. 5 or SEQ ID No. 12, or a homodimer of these peptides. It also includes a nucleic acid that encodes for the peptide with the specified sequences. The pharmaceutical compositions comprising these peptides or nucleic acids are part of this invention. Furthermore, it provides the use of an IL-15 antagonist peptide for the manufacture of a medicament aimed at treating diseases related to IL-15 overexpression, including prostate and kidney cancer.

Another significant patent involves a method to block the infection by flaviviruses. This invention relates to a method for preventing the infection of cells by the dengue virus. It works by interfering with the direct interaction of the viral envelope protein with a cellular receptor or its indirect interaction through a carrier protein. The cellular receptor in question is the alpha-2 macroglobulin receptor, also known as CD91, and the carrier protein is human alpha-2 macroglobulin.

Career Highlights

Ania Cabrales Rico is affiliated with the Centro de Ingeniería Genética y Biotecnología, where she continues to innovate and contribute to the field of genetic engineering and biotechnology. Her work is characterized by a strong focus on developing solutions for pressing medical challenges.

Collaborations

Some of her notable coworkers include Osvaldo Reyes Acosta and Hilda Elisa Garay Perez, who collaborate with her on various projects within the biotechnology sector.

Conclusion

Ania Cabrales Rico's contributions to biotechnology through her innovative patents highlight her role as a leading inventor in the field. Her work not only addresses critical health issues but also showcases the potential of biotechnology in developing effective treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…